GemPharmatech and Humlab Global have signed a strategic agreement to distribute existing and novel humanized mouse strains worldwide, aiming to support more predictive in vivo testing for advanced therapeutics.
GemPharmatech provides genetically engineered animal models and in vivo efficacy testing, while Singapore‑based Humlab develops humanized mouse models and translational research tools. The partners said the rapid evolution of drug modalities has increased demand for preclinical models that better reflect human physiology and improve the odds of clinical translation.
Humlab’s portfolio includes humanized aging models designed to interrogate mechanisms underlying senescence, tissue degeneration, and other hallmarks of aging. Additional strains covered by the agreement support research across autoimmune and inflammatory disease (such as inflammatory bowel disease and systemic lupus erythematosus), metabolic disease including MASH, oncology, and infectious disease.
A key component of the collaboration is Humlab’s humanized liver mouse model, which provides a platform for studying liver‑specific immune and metabolic mechanisms. The companies expect this model to be central for programs targeting hepatic and systemic metabolic conditions.
Under the arrangement, GemPharmatech will add Humlab’s strains to its humanized model library and make them available to global drug developers. Leadership from both organizations said the partnership is intended to expand access to specialized models and offer a more competitive set of tools for translational research.
The agreement reflects growing interest in humanized and aging‑focused mouse systems as biopharmaceutical companies seek better preclinical predictors of efficacy and safety across multiple therapeutic areas.